Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
NCT07270978
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
23
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasm
Interventions
DRUG:
CD33 FPBMC
Sponsor
University of Virginia